Abstract 45
Background 46
In recent years, metagenomic Next-Generation Sequencing (mNGS) has increasingly been used for an accurate assumption-free virological diagnosis. However, the systematic 48 workflow evaluation on clinical respiratory samples and implementation of quality controls 49 (QCs) is still lacking. 50
Methods 51
A total of 3 QCs were implemented and processed through the whole mNGS workflow: a no-52 template-control to evaluate contamination issues during the process; an internal and an 53 external QC to check the integrity of the reagents, equipment, the presence of inhibitors, and 54 to allow the validation of results for each sample. The workflow was then evaluated on 37 55 clinical respiratory samples from patients with acute respiratory infections previously tested 56 for a broad panel of viruses using semi-quantitative real-time PCR assays (28 positive 57 samples including 6 multiple viral infections; 9 negative samples). Selected specimens 58 included nasopharyngeal swabs (n = 20), aspirates (n = 10), or sputums (n = 7). 59
Results 60
The optimal spiking level of the internal QC was first determined in order to be sufficiently 61 detected without overconsumption of sequencing reads. According to QC validation criteria, 62 mNGS results were validated for 34/37 selected samples. For valid samples, viral genotypes 63 were accurately determined for 36/36 viruses detected with PCR (viral genome coverage 64 ranged from 0.6% to 100%, median = 67.7%). This mNGS workflow allowed the detection of 65 DNA and RNA viruses up to a semi-quantitative PCR Ct value of 36. The six multiple viral 66 infections involving 2 to 4 viruses were also fully characterized. A strong correlation between 67 results of mNGS and real-time PCR was obtained for each type of viral genome (R 2 ranged 68 from 0.72 for linear single-stranded (ss) RNA viruses to 0.98 for linear ssDNA viruses). 69
Conclusions 70
Although the potential of mNGS technology is very promising, further evaluation studies are 71 urgently needed for its routine clinical use within a reasonable timeframe. The approach 72 described herein is crucial to bring standardization and to ensure the quality of the generated 73 sequences in clinical setting. We provide an easy-to-use single protocol successfully 74 evaluated for the characterization of a broad and representative panel of DNA and RNA 75 respiratory viruses in various types of clinical samples. 76
Background 77
Since the development of Next Generation-Sequencing (NGS) technologies in 2005, 78 the use of metagenomic approaches has grown considerably. It is now considered as an 79 efficient unbiased tool in clinical virology [1, 2] , in particular for the characterization of viral 80 acute respiratory infections (ARIs). Several advantages of metagenomic NGS (mNGS) 81 compared to conventional real-time Polymerase Chain Reaction (PCR) assays have been 82 highlighted. Firstly, the full viral genetic information is immediately available allowing the 83 investigation of respiratory outbreaks, viral epidemiological surveillance, or identification of 84 specific mutations leading to antiviral resistance or higher virulence [3-5]. Secondly, a 85 significant improvement in viral ARIs diagnosis has been reported [4,6-9]; as the process is 86 sequence independent, mNGS is able to identify highly divergent viral genomes, rare 87 respiratory pathogens, and to discover respiratory viruses missed by targeted PCR [1, 4, 7] . 88 However, the diversity in viral nucleic acid types has impaired the development of a 89 unique viral metagenomic workflow allowing the comprehensive characterization of viruses 90 present in a clinical sample. Most of the published viral metagenomic protocols have been 91 optimized for the detection either of DNA viruses or RNA viruses [4,5,10-13]. In addition, 92 despite the growing number of studies using a metagenomic process in clinical virology, 93 evaluation of workflows has not systematically included both clinical samples and quality 94 control (QC) implementation. A metagenomic protocol involves a large number of steps and 95 all of these have to be controlled to ensure the quality of the generated sequences [6, [14] [15] [16] . 96 Furthermore, specimen to specimen, environmental, and reagent contaminations are also a 97 major concern in metagenomic setting and must be accurately evaluated [6, [17] [18] [19] . 98
The objective of this study was to implement QCs in a single metagenomic protocol and to 99 evaluate it for the detection of a broad panel of DNA and RNA viruses in clinical respiratory 100 samples. 101
Methods 102

Clinical samples 103
A total of 37 respiratory samples collected from patients hospitalized in the university 104 hospital of Lyon (Hospices Civils de Lyon, HCL) were retrospectively selected to evaluate 105 our metagenomic approach. Selected specimens included various types of clinical samples; 106 nasopharyngeal swabs (n=20), aspirates (n=10), or sputums (n=7). These samples were 107 initially sent to our laboratory for routine viral diagnosis of ARI using semi-quantitative real-108 were negative for all the targeted viruses. These 9 samples were also found to be negative 115 using the FilmArray Respiratory Panel (FA RP, bioMérieux). After PCR testing, the rest of 116 samples were stored at -20°C until mNGS analysis. 117
Metagenomic workflow 118
For sample viral enrichment, a 3-step method was applied to 200μl of thawed and vortexed 119 sample [20]: low-speed centrifugation (6000g, 10 min, 4 °C), followed by filtration of the 120 supernatant using 0.80 µm filter (Sartorius, Göttingen, Germany) to remove eukaryotic and 121 bacterial cells, without loss of large viruses [21] and then Turbo DNase treatment (0.1U/μL, 122 37 °C, 90 min; Life Technologies, Carlsbad, CA, USA). Total nucleic acid was extracted 123 using the NucliSENS EasyMAG platform (bioMérieux, Marcy l'Etoile, France) followed by 124 an ethanol precipitation (2 hours at -80°C). As previously described, modified whole 125 transcriptome amplification was performed to amplify both DNA and RNA viral nucleic acids 126 (WTA2, Sigma-Aldrich, Darmstadt, Germany) [21] . Amplified DNA and cDNA were then 127 purified using a QiaQuick column (Qiagen, Hilden, Germany) and quantified using the Qubit 128 fluorometer HS dsDNA Kit (Life Technologies, Carlsbad, CA, USA). Nextera XT 129 DNA Library preparation and Nextera XT Index Kit were used to prepare paired-end 130 libraries, according to the manufacturer's recommendations (Illumina, San Diego, CA, USA). 131
After normalization, a pool of libraries (V/V) was made and quantified using universal KAPA 132 library quantification kit (Kapa Biosystems, Wilmington, MA, USA); 1% PhiX genome was 133 added to the quantified library before sequencing with Illumina NextSeq 500 ™ platform 134 ( Fig. 1 ). In addition, it should be noticed that our wet-lab process was designed to prevent 135 contaminations as much as possible: reagents were stored and prepared in a DNA-free room; 136 patient samples were opened in a laminar flow hood in a pre-PCR room; after the 137 amplification step, tubes were handled and stored in a post-PCR room. 138
Bioinformatic analysis 139
A stepwise bioinformatic filtering pipeline was used to quality filter reads using cutadapt and threshold regarding genome coverage pattern was applied nor requirement to cover a 151 particular region of the genome. This latter requirement could be important to correctly 152 identify RNA virus subtypes with high recombination frequencies within a species, but has to 153 be implemented specifically for each viral family. 154
Quality control implementation 155
All respiratory specimens were spiked with internal quality control (IQC) before sample 156 preparation. MS2 bacteriophage from a commercial kit (MS2, IC1 RNA internal control; r-157 gene, bioMérieux) was selected as the IQC. As positive external quality control (EQC), we 158 used viral transport medium spiked with MS2 at the same concentration used for the IQC. A 159
No-Template Control (NTC) was implemented to evaluate contamination during the process. 160
NTC was constituted of viral transport medium (Sigma-virocult, MWE, Corsham, UK) that 161 was processed through all mNGS steps. Two QC testing (QCT) were performed: QCT1 which 162 was the semi-quantitative detection of MS2 using a commercial real-time PCR assay (IC1 163 RNA internal control, r-gene, bioMérieux,) after amplification step ( Fig. 1 ). QCT1 validation 164 criteria were: MS2 semi-quantitative PCR Cycle threshold (Ct) below 37 Ct for IQC and 165 EQC, and no MS2 detection for NTC. QCT2 evaluated the sequencing performance by 166 quantifying the number of reads aligned on the MS2 genome (in RPKM) and MS2 genome 167 coverage (MS2 genome accession number: NC_001417.2; Fig. 1 ). QCT2 validation criteria 168 were MS2 genome coverage >95% for positive EQC, and an MS2 RPKM > 0 for IQC. 169
Statistical analysis 170
Statistical analyses were performed using GraphPrism version 5.02 applying the appropriate 171 statistical test (associations between mNGS and viral real-time PCR assay were determined 172 by applying the Pearson's correlation coefficient and differences between median and 173 distributions were evaluated by the Mann-Whitney U test). A p-value less than 0.05 was 174 considered to be statistically significant. 175
Results 176
Determination of optimal internal quality control spiking 177 MS2 bacteriophage (MS2), a single-stranded RNA virus (ssRNA), was used as the IQC to 178 validate the whole metagenomic process for each sample. In order to optimize IQC spiking 179 level, the sensitivity of the metagenomic analysis workflow for MS2 detection was first 180 evaluated with a ten-fold serial dilutions of MS2 (from 10 -2 to 10 -5 ) in a nasopharyngeal swab 181 tested negative using FA RP (bioMérieux). MS2 was detected in internal QCT1 (IQCT1) for 182 all levels of MS2 spiking (Ct ranged from 17.5 at the 10 -2 dilution to 26.4 Ct at the 10 -5 183 dilution). Full to partial MS2 genome coverage was obtained for all MS2 spiking levels in 184 internal QCT2 (IQCT2; coverage ranged from 98% at the 10 -2 dilution to 69% at the 10 -5 185 dilution). For the highest spiking level, 66.0% of the total number of viral reads was mapped 186 to MS2; for the lowest spiking level, 0.9% were so (Fig. 2) . To limit the number of NGS reads 187 consumed for IQC detection, the optimal spiking condition was determined to be the 10 -188 5 dilution and was used for the rest of the study. 189 were detected after bioinformatic analysis. For sample # 19, we sequenced a replicate which 214 similarly failed both IQC and HBoV detection. We could not test any replicate for sample # 215 37 owing to insufficient quantity. Viral metagenomics results for sample # 23 were validated 216 as viral reads represented 85.2% (9,489,578/11,144,324) of the total reads generated (Fig. 3) . 217
Validation of mNGS results
For sample # 11, the number of reads mapping to HCoV was 9/5,125,947 with a HCoV 218 genome coverage of 0.2%. Results were therefore not validated for this sample. Overall, 219 mNGS results were validated for 34/37 samples including 26/28 positive samples and 8/9 220 negative samples. 221
Metagenomic workflow evaluation according to viral genome type 222
The evaluation of the metagenomic workflow was performed using the 26 previously 223 Normalized read counts were significantly lower for linear dsDNA viruses than for other viral 237 genome types (Fig. 4b) . 238
Discussion 239
Over the last few years, a growing number of viral metagenomic protocols have been 240 published but systematic evaluation on clinical respiratory samples and validation by QC is 241 still lacking. In the present study, we describe a process allowing the sensitive detection of 242 both DNA and RNA viruses in a single assay and implemented several QCs to validate the 243 whole metagenomic workflow. 244
First, IQC was implemented to control the integrity of the reagents, equipment, the presence 245 of inhibitors, and to allow the validation of mNGS results for each sample. The MS2 246 bacteriophage was selected as IQC for three main reasons; firstly MS2 is widely used as IQC 247 during viral real-time PCR assays to control both extraction and inhibition [24], secondly, an 248 RNA virus was required to control the random reverse transcription and second strand 249 synthesis steps, and thirdly MS2 is a ssRNA virus with a small genome (3,569-bp) that is 250 perfectly characterized and therefore can be easily detected after bioinformatic analysis 251 without the need for extensive NGS reads. The use of MS2 as an IQC has been previously 252 reported for metagenomic analysis of cerebrospinal fluid specimens [25] . In another 253 metagenomic study, RNA of MS2 was included after extraction as an IQC but the use of 254 purified RNA does not validate the viral enrichment step [26]. In the protocol described 255 herein, whole MS2 virions were added to each clinical sample from the beginning of the 256 workflow. QCT1 was implemented to control the first steps of the process and to avoid 257 unnecessary library preparation when these steps fail. At the end of the workflow, QCT2 was 258 able to invalidate 2 samples as neither MS2 nor viruses causing ARIs were significantly 259 detected after metagenomic analysis while routine PCR screenings detected a HBoV and a 260
HCoV. The re-testing of these 2 samples found the same findings suggesting an inhibition or 261 a competition issue during the process. Without the use of IQC, these samples would have 262 been mistakenly classified as false negatives by mNGS. However, the expected competition 263 between viruses and MS2 during the process could lead to a non-detection of IQC reads in 264 case of high viral load. Thus, the interpretation of IQC results should consider the proportion 265 of viral reads of each sample. Although not observed, IQC reads may also be reduced in 266 samples with a greater numbers of patient cells which may affect the sensitivity of the assay 267 [25] . 268
In addition to IQC, we implemented negative external control because contamination issues 269 are frequently reported in metagenomic studies and may lead to misinterpretation in clinical 270 practice [17] . mNGS reads in this negative control were mainly composed of bacterial reads. 271
However, viral reads (mainly derived from prokaryote viruses) were also detected which 272 could be present in reagents ("kitome") or may represent laboratory contaminants or bleed- compared to the other viral genome types were noticed. As previously described for EBV and 302 CMV, the necessary use of DNase to reduce host contamination may affect these fragile large 303 dsDNA viruses [9,10]. As the detection limit of mNGS analysis is mainly dependent on viral 304 load and total number of reads per sample, this effect could be overcome by increasing 305 sequencing depth; however, we chose to limit the costs of the workflow. 306
The reagent cost of this mNGS approach is relatively low and was estimated to ~€150 thanks 307 to our viral enrichment process and the amplification method using a commercial kit which is 308 diluted 5-fold [21] . The use of a universal workflow for both DNA and RNA viruses also 309 reduces the reagent cost compared with metagenomic protocols targeting DNA and RNA 310 viruses separately. In contrast, targeted NGS of specific viruses following their specific 311 amplification by PCR can be up to 2 times cheaper based on our experience (e.g. influenza 312 virus sequencing [29] . Due to several limitations, including its cost and a long turnaround 313 time, viral metagenomics is currently considered to be a second-line approach and is not used 314 as a primary routine diagnostic tool. However, with the improvement of sequencing 315 technologies allowing real-time sequencing such as MinION sequencers (Oxford nanopore, 316
Oxford, United Kingdom), it could be envisioned that mNGS will gradually be used for 317 primary diagnosis in the mid-term. In case of high viral load and sufficient DNA input after 318 amplification our workflow might be used with a MinION sequencer. 319
The approach described in this preliminary work is crucial to bring standardization for the 320 routine clinical use of mNGS process within a reasonable timeframe. Further evaluation 321 studies with a greater number of samples are urgently needed to establish IQC cut-off 322 according to the number of viral, human and bacterial reads, and to define the performance of 323 the workflow, including repeatability, reproducibility, as well as the detection limit for each 324 virus. In addition, improvement of the bioinformatics pipeline are being explored, including 325 implementation of threshold regarding genome coverage pattern [25] , but their impact on 326 performance of the workflow has to be established. 327
Conclusion 328
The potential of mNGS is very promising but several factors such as inhibition, competition, 329 and contamination can lead to a dramatic misinterpretation in the clinical setting. Herein, we 330 provide an efficient and easy to use mNGS workflow including quality controls successfully 331 
